ATE221788T1 - Anti-transformierender wachstumsfaktor beta gentherapie - Google Patents

Anti-transformierender wachstumsfaktor beta gentherapie

Info

Publication number
ATE221788T1
ATE221788T1 AT96905473T AT96905473T ATE221788T1 AT E221788 T1 ATE221788 T1 AT E221788T1 AT 96905473 T AT96905473 T AT 96905473T AT 96905473 T AT96905473 T AT 96905473T AT E221788 T1 ATE221788 T1 AT E221788T1
Authority
AT
Austria
Prior art keywords
tgf
beta
cell
nucleic acid
specific inhibitory
Prior art date
Application number
AT96905473T
Other languages
English (en)
Inventor
Wayne A Border
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Application granted granted Critical
Publication of ATE221788T1 publication Critical patent/ATE221788T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
AT96905473T 1995-02-15 1996-02-14 Anti-transformierender wachstumsfaktor beta gentherapie ATE221788T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/389,887 US5824655A (en) 1995-02-15 1995-02-15 Anti-transforming growth factor-β gene therapy
PCT/US1996/001913 WO1996025178A1 (en) 1995-02-15 1996-02-14 ANTI-TRANSFORMING GROWTH FACTOR-β GENE THERAPY

Publications (1)

Publication Number Publication Date
ATE221788T1 true ATE221788T1 (de) 2002-08-15

Family

ID=23540156

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96905473T ATE221788T1 (de) 1995-02-15 1996-02-14 Anti-transformierender wachstumsfaktor beta gentherapie

Country Status (10)

Country Link
US (1) US5824655A (de)
EP (1) EP0809517B1 (de)
JP (1) JPH11500128A (de)
KR (1) KR19980702268A (de)
AT (1) ATE221788T1 (de)
AU (1) AU694621B2 (de)
CA (1) CA2213198C (de)
DE (1) DE69622846T2 (de)
ES (1) ES2179933T3 (de)
WO (1) WO1996025178A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214375B1 (en) * 1989-09-29 2007-05-08 La Jolla Cancer Research Foundation Methods of decreasing the accumulation of extracellular matrix associated with glomerulonephritis with anti-TGF-β-specific antibodies
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
WO1999021589A2 (de) 1997-10-29 1999-05-06 Axel Wilhelm August Baltzer Verwendung von vektoren wie adenoviren und/oder adeno-assoziierten viren und/oder retroviren und/oder herpes-simplex-viren und/oder liposomen und/oder plasmiden als vehikel für genetische information zur befähigung von säugetierzellen mittel, zur behandlung von knochenpathologien zu produzieren
US6524573B1 (en) 1997-12-30 2003-02-25 Thomas Jefferson University Method of suppressing tumor cell growth by administering a decorin gene or gene product
WO1999033342A1 (en) * 1997-12-30 1999-07-08 Thomas Jefferson University Method of suppressing tumor cell growth by administering decorin
CA2336472C (en) * 1998-07-03 2010-08-31 Dnavec Research Inc. Negative-sense rna virus vector for nerve cell
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
EP2130532A1 (de) * 1999-01-05 2009-12-09 University of Utah Research Foundation Verfahren zur Behandlung von mit der Akkumulation von überschüssiger extrazellulärer Matrix assoziierten Zuständen
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
ES2398039T3 (es) 2000-03-09 2013-03-13 Genzyme Corporation Uso de anticuerpos antagonistas anti-TGF-beta para tratar o prevenir la pérdida de función renal
US7101543B2 (en) 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
EP1267945B8 (de) * 2000-03-31 2012-03-21 NovaRx Genetisch modifizierte zellen, welche einen tgf-beta inhibitor exprimieren, wobei die zellen lungenkrebszellen sind
AU2001259174A1 (en) * 2000-04-28 2001-11-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
EP1294391B1 (de) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Wirkstoffkombination zur verhinderung der transplantatabstossung
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
WO2002002638A2 (en) 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
AU2003209308A1 (en) * 2002-01-22 2003-09-02 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
WO2004056352A1 (en) * 2002-12-19 2004-07-08 Scios, Inc. TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-β INHIBITORS
ATE531803T1 (de) * 2003-06-05 2011-11-15 Ajinomoto Kk Fermentierungsverfahren mittels veränderter bakterien mit einer erhöhten aufnahme von nebenprodukten
DE602004025810D1 (de) * 2003-06-30 2010-04-15 Dnavec Research Inc Negativ-strang rna-virus-vektoren, welche ein gen mit veränderten hypermutierbaren regionen tragen
WO2005016254A2 (en) * 2003-07-16 2005-02-24 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
CN1852741A (zh) * 2003-07-16 2006-10-25 Rvx治疗公司 下调TGF－β效应的化合物和方法
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
JP2008508888A (ja) * 2004-08-05 2008-03-27 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 細胞活性化のための方法および組成物
JP5481028B2 (ja) * 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連リンパ増殖性障害を処置または予防するための方法
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
KR100747646B1 (ko) * 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
JP5602365B2 (ja) 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
US7582609B2 (en) 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
DK2083863T3 (da) 2006-10-03 2015-06-22 Genzyme Corp Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi
JP2010529859A (ja) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション ＴＧＦ−βＩＩ型受容体の２つのＴＧＦ−β結合ドメインを含有する融合タンパク質
US20090124570A1 (en) * 2007-11-08 2009-05-14 University Of Maryland, Baltimore Methods and Compositions for Facilitating Tissue Repair and Diagnosing, Preventing, and Treating Fibrosis
FR2943249B1 (fr) 2009-03-18 2011-08-12 Genethon Utilisation de la decorine pour augmenter la masse musculaire
US9409963B2 (en) 2009-05-26 2016-08-09 The Regents Of The University Of California Fibromodulin peptide
ES2584433T3 (es) 2010-03-12 2016-09-27 Genzyme Corporation Terapia de combinación para tratar cáncer de mama
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
EP2737083A1 (de) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Verfahren zur diagnose und behandlung des myhre-syndroms
US9468612B2 (en) 2011-10-26 2016-10-18 Seattle Children's Hospital Cysteamine in the treatment of fibrotic disease
JP6218229B2 (ja) 2011-12-28 2017-10-25 京都府公立大学法人 角膜内皮細胞の培養正常化
WO2013149094A1 (en) 2012-03-28 2013-10-03 The Board Of Regents Of The University Of Texas System TGFβ TYPE II-TYPE III RECEPTOR FUSIONS
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2122491A1 (en) * 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
AU3178893A (en) * 1991-11-15 1993-06-15 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
DE69228700T2 (de) * 1991-12-04 1999-09-09 Jolla Cancer Res Found Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
AU4111893A (en) * 1992-04-23 1993-11-29 La Jolla Cancer Research Foundation Methods for treating vascular disorders by inhibiting the endothelin stimulatory activity of TGFbeta

Also Published As

Publication number Publication date
US5824655A (en) 1998-10-20
CA2213198A1 (en) 1996-08-22
DE69622846D1 (de) 2002-09-12
WO1996025178A1 (en) 1996-08-22
ES2179933T3 (es) 2003-02-01
JPH11500128A (ja) 1999-01-06
DE69622846T2 (de) 2003-04-24
EP0809517B1 (de) 2002-08-07
AU4922096A (en) 1996-09-04
AU694621B2 (en) 1998-07-23
CA2213198C (en) 2002-12-03
EP0809517A1 (de) 1997-12-03
KR19980702268A (ko) 1998-07-15

Similar Documents

Publication Publication Date Title
ATE221788T1 (de) Anti-transformierender wachstumsfaktor beta gentherapie
Dutta et al. Regulation of myelin structure and conduction velocity by perinodal astrocytes
Naldaiz‐Gastesi et al. The panniculus carnosus muscle: an evolutionary enigma at the intersection of distinct research fields
Yuan et al. Epithelial–mesenchymal transition in the formation of hypertrophic scars and keloids
Micera et al. Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair
Richards et al. De novo generation of neuronal cells from the adult mouse brain.
Karagiannides et al. Altered expression of C/EBP family members results in decreased adipogenesis with aging
Godwin et al. Macrophages are required for adult salamander limb regeneration
Landis et al. Neural crest cell lineages
Sirén et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Prinz et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products
Li et al. Transitions between epithelial and mesenchymal states during cell fate conversions
Taton et al. General inhibition by transforming growth factor β1 of thyrotropin and cAMP responses in human thyroid cells in primary culture
KR960703014A (ko) Mhc 분자 hla-c-클론 10과 복합체를 형성하는 분리된 펩티드 및 그것의 사용(isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof)
KR20090086066A (ko) 당뇨성 창상 치유에 유용한 방법 및 조성물
Stefkovich et al. Dpp4+ interstitial progenitor cells contribute to basal and high fat diet-induced adipogenesis
AU5911499A (en) Leptin induced genes
FR2805821B1 (fr) Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
Wernig et al. The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
Muneoka et al. Evolution of epimorphosis in mammals
Gardahaut et al. Developmental modulation of myosin expression by thyroid hormone in avian skeletal muscle
Kroiher et al. Pattern of cell proliferation in embryogenesis and planula development of Hydractinia echinata predicts the postmetamorphic body pattern
JP2004537274A5 (de)
Sulkin et al. Histochemical Determination of Ribose Nucleic Acid in Vertebrate Tissues Following Extraction with Perchloric Acid.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee